Skip to main content
Contact Us
Subscribe
E-Edition
92°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cytrx Corp
(OP:
CYTR
)
N/A
UNCHANGED
Last Price
Updated: 1:53 PM EDT, Oct 5, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cytrx Corp
< Previous
1
2
Next >
LadRx Corporation Announces OTCQB Ticker Change to LADX
October 05, 2022
From
LadRx Corporation
Via
Business Wire
CytRx Corporation Relaunches as LadRx Corporation
September 23, 2022
From
CytRx Corporation
Via
Business Wire
European Patent Office Awards CytRx Key Patent
September 07, 2022
From
CytRx Corporation
Via
Business Wire
CytRx Welcomes Cary J. Claiborne to the CytRx Board of Directors
August 09, 2022
From
CytRx Corporation
Via
Business Wire
CytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common Stock
May 19, 2022
From
CYTRX CORPORATION
Via
Business Wire
CytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc.
May 17, 2022
From
CytRx Corporation
Via
Business Wire
CytRx Partners with Oncology Development Expert to Advance LADR Platform
April 20, 2022
From
CytRx Corporation
Via
Business Wire
CytRx Issues Open Letter to Stockholders Regarding Recent Corporate Progress
March 21, 2022
From
CytRx Corporation
Via
Business Wire
CytRx Comments on Orphazyme's Update on European Union Regulatory Review of Arimoclomol in Niemann-Pick Disease Type C
February 24, 2022
From
CytRx Corporation
Via
Business Wire
CytRx Highlights Orphazyme's Update on Planned NDA Resubmission for Arimoclomol in Niemann-Pick Disease Type C
February 14, 2022
From
CytRx Corporation
Via
Business Wire
CytRx to Hold Town Hall for Stockholders on Thursday, January 20th
January 18, 2022
From
CytRx Corporation
Via
Business Wire
CytRx to Participate in the H.C. Wainwright BioConnect Virtual Conference
January 07, 2022
From
CytRx Corporation
Via
Business Wire
CytRx Announces the Appointment of Dr. Stephen Snowdy as Chief Executive Officer
January 03, 2022
From
CytRx Corporation
Via
Business Wire
CytRx Highlights ImmunityBio's Use of Aldoxorubicin in Ongoing Clinical Studies for Various Forms of Cancer
December 21, 2021
From
CytRx Corporation
Via
Business Wire
CytRx Provides a Bold Vision on Centurion BioPharma's Plans for a State-of-the-Art Cancer Center in Las Vegas, Nevada
November 30, 2021
From
CytRx Corporation
Via
Business Wire
CytRx Comments on Quarterly Results and Recent Strategic Initiatives
November 12, 2021
From
CytRx Corporation
Via
Business Wire
CytRx Announces Centurion BioPharma Has Been Invited to Present Plans for a State-of-the-Art Cancer Center in Las Vegas, Nevada
November 09, 2021
From
CytRx Corporation
Via
Business Wire
CytRx Highlights Orphazyme's Update on Productive Meeting with FDA Regarding Arimoclomol in Niemann-Pick Disease Type C
November 02, 2021
From
CytRx Corporation
Via
Business Wire
CytRx Highlights ImmunityBio's Completion of Enrollment in Phase 2 Study of Advanced Metastatic Pancreatic Cancer Treatment
October 14, 2021
From
CytRx Corporation
Via
Business Wire
CytRx to Present at Upcoming Virtual LD Micro Conference
October 05, 2021
From
CytRx Corporation
Via
Business Wire
CytRx to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 08, 2021
From
CytRx Corporation
Via
Business Wire
CytRx Highlights Orphazyme’s Published Results From Its Phase 2/3 Trial of Arimoclomol in Niemann-Pick Disease Type C
August 24, 2021
From
CytRx Corporation
Via
Business Wire
CytRx Comments on Quarterly Results and Recent Strategic Initiatives
August 12, 2021
From
CytRx Corporation
Via
Business Wire
CytRx Announces Director Election Results from 2021 Annual Meeting of Stockholders
July 29, 2021
From
CytRx Corporation
Via
Business Wire
CytRx Highlights Preliminary Results of Cohort C of QUILT 88, a Phase 2 Pancreatic Cancer Trial That Includes Aldoxorubicin, Expected to be Released in Q1 2022
July 29, 2021
From
CytRx Corporation
Via
Business Wire
CytRx Corporation Announces Closing of $10 Million Offering to Healthcare-Focused Institutional Investor
July 16, 2021
From
CytRx Corporation
Via
Business Wire
CytRx Corporation Enters Into Securities Purchase Agreement for $10 Million With Healthcare-Focused Institutional Investor
July 13, 2021
From
CytRx Corporation
Via
Business Wire
CytRx Comments on Orphazyme’s Promising 24-Month Interim Trial Results of Arimoclomol for Niemann-Pick Disease Type C
June 30, 2021
From
CytRx Corporation
Via
Business Wire
CytRx Notes Orphazyme’s Regulatory Update from the FDA on Arimoclomol for Niemann-Pick Disease Type C
June 18, 2021
From
CytRx Corporation
Via
Business Wire
CytRx to Present at Upcoming Investor Conferences
June 02, 2021
From
CytRx Corporation
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.